Development of a microRNA-based prognostic model for accurate prediction of distant metastasis in breast cancer patients
Por:
Fontana, A, Barbano, R, Pasculli, B, Mazza, T, Palumbo, O, Binda, E, Trivieri, N, Mencarelli, G, Laurenzana, I, Lamorte, D, De Luca, L, Caivano, A, Biagini, T, Rendina, M, lo Mele, A, Prencipe, G, Bravaccini, S, Murgo, R, Ciuffreda, L, Morritti, M, Valori, VM, Di Lisa, FS, Vici, P, Castelvetere, M, Carella, M, Graziano, P, Maiello, E, Copetti, M, Esteller, M and Parrella, P
Publicada:
29 sep 2025
Ahead of Print:
29 sep 2025
Resumen:
BackgroundThe attempt to exploit molecular subtyping for risk stratification in breast cancer patients has been only partially successful with a limited application in the clinical practice. In the BREMIR study, we aimed to identify a panel of miRNAs as prognostic biomarkers for breast cancer. We first confirmed the association of previously linked miRNAs with critical clinical parameters, then adopted a discovery-driven approach to identify novel biomarkers.MethodsmiRNA expression was analyzed using the Affymetrix Gene Chip 4.0 array in a discovery cohort of 34 patients (3 with synchronous metastases, 14 who developed metastases after 10 years, and 17 who remained metastasis-free) and 6 controls. RT-qPCR validated selected miRNAs in an extended cohort (n = 223) with a median follow up of 6.6 years. A stepwise logistic regression model incorporating miRNA levels and clinicopathological features was developed to predict metastasis risk. Additionally, miRNA expression was assessed in plasma extracellular vesicles (EVs) using digital PCR in an independent cohort (n = 39). In silico enrichment analyses explored the functional role of relevant miRNAs in metastasis development.ResultsEight differentially expressed miRNAs were identified in the discovery cohort. In the extended cohort, miR-3916 and miR-3613-5p were the most effective in distinguishing patients who developed metastases. Higher miR-3916 expression was associated with reduced metastasis risk (OR = 0.42, 95%CI 0.23-0.70, p = 0.002), while higher miR-3613-5p expression was linked to increased risk (OR = 2.06, 95%CI 1.27-3.50, p = 0.005). Adding these miRNAs to a model with clinicopathological features improved discrimination (AUC = 0.85 vs. AUC = 0.76, p = 0.001). The model was effective across all breast cancer subtypes. In extracellular vesicles, miR-3613-5p was more abundant in tumors than benign lesions (p = 0.039), while miR-3916 was lower in metastatic samples than in non-metastatic tumors (p = 0.020). In-silico pathway enrichment analyses indicates their involvement in critical steps of the metastatic process including EMT plasticity, DNA damage response and metastatic niche formation.ConclusionsThis is the first study integrating miRNA expression with clinicopathological features in a logistic model for breast cancer prognosis. While further validation is needed, our model shows promise as a prognostic tool across all breast cancer subtypes. In silico pathway enrichment analysis highlights miR-3613-5p and miR-3916 as critical regulators of metastasis development, underscoring the need for further investigation.Trial registrationClinicalTrials.gov ID NCT06555354 retrospectively registered on August 14th, 2024.
Filiaciones:
Fontana, A:
IRCCS, Fdn Casa Sollievo Sofferenza, Unit Biostat, I-71013 San Giovanni Rotondo, Italy
Barbano, R:
IRCCS, Fdn Casa Sollievo Sofferenza, Lab Oncol, I-71013 San Giovanni Rotondo, Italy
IRCCS, Fdn Casa Sollievo Sofferenza, Unit Transfus Med, Chem Clin Anal Lab, I-71013 San Giovanni Rotondo, Italy
Pasculli, B:
IRCCS, Fdn Casa Sollievo Sofferenza, Lab Oncol, I-71013 San Giovanni Rotondo, Italy
Mazza, T:
Fdn Policlin Univ Agostino Gemelli IRCCS, Computat Biol & Bioinformat Unit, Rome, Italy
Palumbo, O:
RCCS, Fdn Casa Sollievo Sofferenza, Unit Med Genet, I-71121 San Giovanni Rotondo, Italy
Binda, E:
IRCCS, Fdn Casa Sollievo Sofferenza, Canc Stem Cells Unit, Inst Stem Cell Biol Regenerat Med & Innovat Thera, I-71013 San Giovanni Rotondo, Italy
Trivieri, N:
IRCCS, Fdn Casa Sollievo Sofferenza, Canc Stem Cells Unit, Inst Stem Cell Biol Regenerat Med & Innovat Thera, I-71013 San Giovanni Rotondo, Italy
Mencarelli, G:
IRCCS, Fdn Casa Sollievo Sofferenza, Canc Stem Cells Unit, Inst Stem Cell Biol Regenerat Med & Innovat Thera, I-71013 San Giovanni Rotondo, Italy
Laurenzana, I:
Ctr Riferimento Oncol Basilicata IRCCS CROB, Lab Preclin & Translat Res, I-85028 Rionero In Vulture, PZ, Italy
Lamorte, D:
Ctr Riferimento Oncol Basilicata IRCCS CROB, Lab Preclin & Translat Res, I-85028 Rionero In Vulture, PZ, Italy
De Luca, L:
Ctr Riferimento Oncol Basilicata IRCCS CROB, Unit Clin Pathol, I-85028 Rionero In Vulture, PZ, Italy
Caivano, A:
Ctr Riferimento Oncol Basilicata IRCCS CROB, Unit Clin Pathol, I-85028 Rionero In Vulture, PZ, Italy
Biagini, T:
Fdn Policlin Univ Agostino Gemelli IRCCS, Computat Biol & Bioinformat Unit, Rome, Italy
Rendina, M:
IRCCS, Fdn Casa Sollievo Sofferenza, Lab Oncol, I-71013 San Giovanni Rotondo, Italy
lo Mele, A:
IRCCS, Fdn Casa Sollievo Sofferenza, Lab Oncol, I-71013 San Giovanni Rotondo, Italy
Prencipe, G:
IRCCS, Fdn Casa Sollievo Sofferenza, Lab Oncol, I-71013 San Giovanni Rotondo, Italy
Bravaccini, S:
IRCCS, Ist Sci Romagnolo Studio & Cura Tumori IRST, Biosci Lab, Meldola, Italy
Univ Enna Kore, Dept Med & Surg, I-94100 Enna, Italy
Murgo, R:
Fdn Casa Sollievo Sofferenza, Breast Unit, San Giovanni Rotondo, Italy
Ciuffreda, L:
Fdn Casa Sollievo Sofferenza, Breast Unit, San Giovanni Rotondo, Italy
Morritti, M:
IRCCS, Fdn Casa Sollievo Sofferenza, Unit Oncol, I-71013 San Giovanni Rotondo, Italy
Valori, VM:
IRCCS, Fdn Casa Sollievo Sofferenza, Unit Oncol, I-71013 San Giovanni Rotondo, Italy
Di Lisa, FS:
IRCCS, Regina Elena Natl Canc Inst, I-00144 Rome, Italy
Vici, P:
IRCCS, Regina Elena Natl Canc Inst, I-00144 Rome, Italy
Castelvetere, M:
Sapienza Univ Rome, Dept Radiol Oncol & Pathol Sci, I-00185 Rome, Italy
Carella, M:
RCCS, Fdn Casa Sollievo Sofferenza, Unit Med Genet, I-71121 San Giovanni Rotondo, Italy
Graziano, P:
Sapienza Univ Rome, Dept Radiol Oncol & Pathol Sci, I-00185 Rome, Italy
Maiello, E:
IRCCS, Fdn Casa Sollievo Sofferenza, Unit Oncol, I-71013 San Giovanni Rotondo, Italy
Copetti, M:
IRCCS, Fdn Casa Sollievo Sofferenza, Unit Biostat, I-71013 San Giovanni Rotondo, Italy
:
Josep Carreras Leukemia Res Inst IJC, Barcelona, Catalonia, Spain
Ctr Invest Biomed Red Canc CIBERONC, Madrid, Spain
Institucio Catalana Recerca & Estudis Avancats IC, Barcelona, Catalonia, Spain
Univ Barcelona UB, Sch Med & Hlth Sci, Physiol Sci Dept, Barcelona, Catalonia, Spain
Parrella, P:
IRCCS, Fdn Casa Sollievo Sofferenza, Lab Oncol, I-71013 San Giovanni Rotondo, Italy
Green Submitted, gold
|